Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy

Exclusion Criteria

• •Taking opioids for greater than 4 days per week prior to screening
• •Has a history of advanced renal disease or severe liver disease (within the last 6 months)
• •Receiving emicizumab while also receiving activated prothrombin complex concentrate (FEIBA)
• •Uncontrolled or poorly controlled hypertension
• •History of major cardiac or cerebrovascular disease
• •History of an upper GI perforation, obstruction, or major GI bleed or current evidence of GI bleeding
• •Has active hepatitis C or hepatitis B infection or uncontrolled HIV. Note: Patients who are HIV positive are allowed to participate if considered to be controlled.
• •Has a positive drug screen for all prohibited drugs of potential abuse at screening
• •Has had an intra-articular injection (within 3 months), initiated physical therapy (within 30 days) or has had orthopedic surgery (within 4 months) prior to screening